TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

  1. Home
  2. purchase Customization

purchase customization

Leave This Empty:

choose chapter to purchase


Back to Report

table of content

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Nonalcoholic Steatohepatitis (NASH)
1.2 Key Market Segments
1.2.1 Nonalcoholic Steatohepatitis (NASH) Segment by Type
1.2.2 Nonalcoholic Steatohepatitis (NASH) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Nonalcoholic Steatohepatitis (NASH) Market Overview
2.1 Global Market Overview
2.1.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Nonalcoholic Steatohepatitis (NASH) Market Competitive Landscape
3.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Manufacturers (2019-2024)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2019-2024)
3.3 Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Nonalcoholic Steatohepatitis (NASH) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Nonalcoholic Steatohepatitis (NASH) Sales Sites, Area Served, Product Type
3.6 Nonalcoholic Steatohepatitis (NASH) Market Competitive Situation and Trends
3.6.1 Nonalcoholic Steatohepatitis (NASH) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Nonalcoholic Steatohepatitis (NASH) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Nonalcoholic Steatohepatitis (NASH) Industry Chain Analysis
4.1 Nonalcoholic Steatohepatitis (NASH) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Nonalcoholic Steatohepatitis (NASH) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Nonalcoholic Steatohepatitis (NASH) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2019-2024)
6.3 Global Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2019-2024)
6.4 Global Nonalcoholic Steatohepatitis (NASH) Price by Type (2019-2024)
7 Nonalcoholic Steatohepatitis (NASH) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Nonalcoholic Steatohepatitis (NASH) Market Sales by Application (2019-2024)
7.3 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2019-2024)
7.4 Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2019-2024)
8 Nonalcoholic Steatohepatitis (NASH) Market Segmentation by Region
8.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.1.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.1.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region
8.2 North America
8.2.1 North America Nonalcoholic Steatohepatitis (NASH) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Nonalcoholic Steatohepatitis (NASH) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 AstraZeneca
9.1.1 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Basic Information
9.1.2 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Overview
9.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Arena Pharmaceuticals
9.2.1 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
9.2.2 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
9.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.2.4 Arena Pharmaceuticals Business Overview
9.2.5 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
9.2.6 Arena Pharmaceuticals Recent Developments
9.3 GSK
9.3.1 GSK Nonalcoholic Steatohepatitis (NASH) Basic Information
9.3.2 GSK Nonalcoholic Steatohepatitis (NASH) Product Overview
9.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.3.4 GSK Nonalcoholic Steatohepatitis (NASH) SWOT Analysis
9.3.5 GSK Business Overview
9.3.6 GSK Recent Developments
9.4 Novo Nordisk
9.4.1 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Basic Information
9.4.2 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Overview
9.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.4.4 Novo Nordisk Business Overview
9.4.5 Novo Nordisk Recent Developments
9.5 Roche
9.5.1 Roche Nonalcoholic Steatohepatitis (NASH) Basic Information
9.5.2 Roche Nonalcoholic Steatohepatitis (NASH) Product Overview
9.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.5.4 Roche Business Overview
9.5.5 Roche Recent Developments
9.6 Vivus
9.6.1 Vivus Nonalcoholic Steatohepatitis (NASH) Basic Information
9.6.2 Vivus Nonalcoholic Steatohepatitis (NASH) Product Overview
9.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.6.4 Vivus Business Overview
9.6.5 Vivus Recent Developments
9.7 Arisaph Pharmaceuticals
9.7.1 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
9.7.2 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
9.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.7.4 Arisaph Pharmaceuticals Business Overview
9.7.5 Arisaph Pharmaceuticals Recent Developments
9.8 Cempra Pharmaceuticals
9.8.1 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
9.8.2 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
9.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.8.4 Cempra Pharmaceuticals Business Overview
9.8.5 Cempra Pharmaceuticals Recent Developments
9.9 Galectin Therapeutics
9.9.1 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Basic Information
9.9.2 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Overview
9.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.9.4 Galectin Therapeutics Business Overview
9.9.5 Galectin Therapeutics Recent Developments
9.10 Galmed Pharmaceuticals
9.10.1 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Basic Information
9.10.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
9.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.10.4 Galmed Pharmaceuticals Business Overview
9.10.5 Galmed Pharmaceuticals Recent Developments
9.11 Genfit
9.11.1 Genfit Nonalcoholic Steatohepatitis (NASH) Basic Information
9.11.2 Genfit Nonalcoholic Steatohepatitis (NASH) Product Overview
9.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.11.4 Genfit Business Overview
9.11.5 Genfit Recent Developments
9.12 Gilead
9.12.1 Gilead Nonalcoholic Steatohepatitis (NASH) Basic Information
9.12.2 Gilead Nonalcoholic Steatohepatitis (NASH) Product Overview
9.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Product Market Performance
9.12.4 Gilead Business Overview
9.12.5 Gilead Recent Developments
10 Nonalcoholic Steatohepatitis (NASH) Market Forecast by Region
10.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast
10.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
10.2.3 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Region
10.2.4 South America Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Nonalcoholic Steatohepatitis (NASH) by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Nonalcoholic Steatohepatitis (NASH) by Type (2025-2030)
11.1.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Nonalcoholic Steatohepatitis (NASH) by Type (2025-2030)
11.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Application (2025-2030)
11.2.1 Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) Forecast by Application
11.2.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings